|
Dubai – Amal Alrashedi Lawyers & Legal ConsultantsPerfect has announced the appointment of Dr Hassan Elhais as Legal Consultant, marking a significant expansion of the firm’s legal expertise and strengthening its international standing. Dr Elhais brings nearly two decades of … Continue reading →
|
mental health services Keller TX Discover top mental health services in Keller, TX, to boost your well-being with expert care and support for a healthier, happier life. Keller, TX – Mind Above Matter, a trusted mental health service provider in … Continue reading →
|
|
Chronic Rhinosinusitis with Nasal Polyps Clinical Trial Companies active in the Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) space include Keymed Biosciences, Connect Biopharma, AstraZeneca, Amgen, Pfizer, Trellis Bioscience LLC, GlaxoSmithKline, Gossamer Bio, Biohaven Pharmaceuticals, Insmed Incorporated, Lyra Therapeutics, and several … Continue reading →
|
Vasculitis Pipeline Leading companies involved in the Vasculitis therapeutic space include R-Pharm Overseas, AbbVie, Toleranzia, Ambulero, Visterra, CytoDyn, ChemoCentryx, Hoffmann-La Roche, GlaxoSmithKline, Vifor Pharma, Beijing Defengrei Biotechnology, InflaRx, Janssen Biotech, Novartis, Oxitope Pharma, Eli Lilly and Company, Travere Therapeutics, Caladrius … Continue reading →
|
|
Diagnostic Imaging Equipment Market The global diagnostic imaging equipment market is projected to grow from USD 51,560.07 million in 2025. Also, Market growth is largely attributed to the increasing burden of chronic illnesses such as cardiovascular diseases, cancer, neurological disorders, … Continue reading →
|
Juvenile Idiopathic Arthritis Market Leading Juvenile Idiopathic Arthritis Companies include Bristol-Myers Squibb, UCB Biopharma, Novartis, AbbVie, Sanofi, Regeneron Pharmaceuticals, Janssen Pharmaceutical, Eli Lilly, Sobi, Pfizer, and others The Juvenile Idiopathic Arthritis (JIA) market is witnessing consistent expansion, fueled by increasing … Continue reading →
|
|
Orforglipron Market Global momentum builds around investigational oral GLP-1 receptor agonist Orforglipron as Phase III data signal strong commercial and clinical potential The global metabolic disorder treatment landscape is on the brink of significant transformation as Orforglipron, an investigational once-daily … Continue reading →
|
DelveInsight’s “Melanoma Pipeline Insights 2026” report provides comprehensive insights about 150+ companies and 170+ pipeline drugs in the Melanoma Pipeline landscape. It covers the Melanoma Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Melanoma pipeline … Continue reading →
|
|
DelveInsight’s “Major Depressive Disorder Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Major Depressive Disorder pipeline landscape. It covers the Major Depressive Disorder pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →
|
DelveInsight’s “Lou Gehrig’s disease Pipeline Insight, 2026” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Lou Gehrig’s disease pipeline landscape. It covers the Lou Gehrig’s disease pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →
|